Despite Global Crisis, China’s Strongest Pharma Firms Likely To Thrive In 2009 Through Innovation And Acquisitions
This article was originally published in PharmAsia News
BEIJING - Despite the Western world's financial meltdown and China's own faltering economic growth rates, the country's leading pharmaceutical companies are forecast to expand through 2009 by developing innovative drugs and by outlasting or even merging with their weakest competitors
You may also be interested in...
SHANGHAI - China will invest RMB 6.6 billion ($960 million) to launch a massive new drug development and manufacturing program from 2008 to 2010. Roughly 3,290 projects focused on preclinical studies and identifying new candidates are awaiting approval to initiate in 2009
BEIJING - China's new plan to inject RMB 4 trillion into the economy to stimulate growth and counter the effects of the global financial crisis will boost the overall health care sector and propel medical system reforms, according to analysts
China’s Health System Reforms Set To Spark Hospital Construction Boom And Boost Medical Device Makers
[Editor's note: This is part two in a new series on China's wide-ranging plans to reform the country's health system, including its hospitals, insurance schemes and access to medicines. Part one appeared in PharmAsia News on Oct. 30, 2008.]